

**Supplementary Table 1. General baseline parameters of the eight non-IMN subgroups**

Parameter	IgAN (n = 106)	MCD (n = 32)	FSGS (n = 22)	DN (n = 35)	LN <sup>a</sup> (n = 16)	HBV-GN <sup>b</sup> (n = 5)	SMN (n = 32)	Others <sup>b</sup> (n = 48)
Male sex	64 (60.4)	18 (56.35)	11 (50.0)	24 (68.6)	6 (35.3)	4 (80.0)	9 (28.1)	31 (64.6)
Age, yr	35 (28–47)	39 ± 15	43 ± 14	49 (43–52)	36 ± 14	43 ± 6	37 ± 13	46 ± 14
WBC, 10 <sup>9</sup> /L	6.66 ± 1.53	5.91 (5.05–6.91)	5.83 ± 1.37	6.46 (5.46–7.85)	5.39 ± 2.93	5.21 ± 1.42	4.66 (3.28–7.90)	6.37 (5.20–8.53)
Hemoglobin, g/L	137 ± 21	152 ± 16	140 ± 27	116 (102–141)	108 (83–126)	127 ± 32	124 ± 24	131 ± 28
Platelet, 10 <sup>9</sup> /L	259 ± 62	265 ± 40	258 ± 52	258 (219–316)	178 ± 78	198 ± 84	179 (161–238)	264 ± 74
Total protein, g/L	28.7 ± 4.1	45.1 (41.8–61.9)	60.3 ± 12.0	60.5 ± 10.0	52.4 ± 10.9	61.9 ± 10.3	52.9 ± 9.6	69.0 (59.7–75.8)
Albumin, g/L	39.2 (34.8–42.3)	20.9 (15.8–36.1)	34.6 (21.8–42.0)	32.4 ± 8.1	24.3 ± 7.1	34.1 ± 5.0	24.7 ± 7.1	40.1 (34.0–42.7)
Globulin, g/L	28.7 ± 4.1	26.1 ± 3.1	27.0 ± 3.3	28.2 ± 3.8	28.1 ± 6.9	27.8 ± 5.5	28.0 ± 5.2	29.1 ± 6.0
BUN, mg/dL	16.4 (12.5–21.6)	14.0 (10.9–19.5)	16.7 (13.7–21.8)	21.6 (16.8–33.9)	27.5 (19.3–39.8)	18.4 ± 4.5	15.6 ± 6.2	22.0 (14.6–28.5)
Serum creatinine, mg/dL	1.0 (0.8–1.4)	0.8 (0.6–1.0)	1.0 ± 0.6	1.2 (0.91.6)	1.2 (0.8–1.6)	1.2 ± 0.4	0.7 (0.6–0.8)	1.4 (0.8–2.1)
eGFR, mL/min/1.73 m <sup>2</sup>	83 ± 32	107 (81–122)	84 ± 39	69 ± 25	70 ± 32	79 ± 31	109 ± 23	62 (31–89)
CysC, mg/L	1.10 (0.86–1.55)	0.93 (0.72–1.26)	1.28 ± 0.52	1.56 (1.12–2.10)	1.94 (1.33–2.62)	1.41 ± 0.37	1.21 ± 0.38	1.67 (1.11–2.20)
Cholesterol, mg/dL	205.3 (179.4–249.9)	349.6 (218.0–444.8)	274.3 ± 94.4	233.2 (174.0–276.5)	272.0 ± 84.7	224.9 ± 91.8	279.2 ± 82.8	194.9 (166.7–266.4)
HDL-C, mg/dL	46.4 (38.8–55.6)	63.2 (51.5–73.8)	49.6 ± 11.4	48.8 ± 12.1	48.4 ± 15.3	49.7 ± 8.6	50.7 (41.4–69.6)	45.6 (35.6–52.6)
LDL-C, mg/dL	129.2 (106.1–159.8)	227.2 (131.5–309.6)	175.0 (121.4–222.7)	137.7 (104.0–182.5)	147.7 (128.4–225.4)	137.7 ± 61.1	176.5 ± 61.9	123.4 (99.0–162.0)
Anti-PLA2R, RU/mL	< 2 <sup>c</sup>	< 2 (< 2–2)	< 2 <sup>c</sup>	< 2 <sup>c</sup>	< 2 (< 2–2.08)	< 2 <sup>c</sup>	< 2 <sup>c</sup>	< 2 <sup>c</sup>
U-RBC, HPF	11.6 (2.8–46.0)	1.7 (0.8–2.7)	2.7 (1.1–6.7)	3.7 (1.1–6.8)	23.4 (5.7–105.8)	8.7 (3.1–47.7)	5.3 (2.2–16.8)	1.7 (0.6–4.2)
Urinary protein, g/day	1.42 (0.59–3.11)	5.20 ± 3.89	3.00 (1.79–5.43)	3.92 (1.87–6.86)	2.95 (1.70–9.35)	3.97 ± 3.65	2.73 (1.58–4.38)	1.62 (0.75–3.60)

Values are presented as number (%), mean ± SD, or median (interquartile range).

IMN, idiopathic membranous nephropathy; IgAN, IgA nephropathy; MCD, minimal change disease; FSGS, focal and segmental glomerulosclerosis; DN, diabetic nephropathy; LN, lupus nephritis; HBV-GN, hepatitis B virus-associated glomerulonephritis; SMN, secondary membranous nephropathy; WBC, white blood cell; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; CysC, serum cystatin C; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; PLA2R, phospholipase A2 receptor; U-RBC, urinary red blood cell.

<sup>a</sup>The subgroup did not include those whose pathological type were (secondary) membranous nephropathy.

<sup>b</sup>The other nephropathy patients included 19 patients with hypertensive renal damage, nine patients with interstitial nephritis, five patients with plasmacytoma-associated nephropathy, four patients with primary renal amyloidosis, four patients with purpura nephritis, two patients with membranoproliferative glomerulonephritis, one patient with endocapillary proliferative glomerulonephritis, one patient with C3 glomerulonephritis, two patients with acute tubular necrosis, and one patient with mild glomerular ischemia with chronic interstitial fibrosis.

<sup>c</sup>All three quartiles of anti-PLA2R were less than 2 RU/mL.